Literature DB >> 23556068

First-line treatment of chronic myeloid leukaemia.

Michael O'Dwyer.   

Abstract

Since the introduction of imatinib just over a decade ago, there has been a dramatic change in the treatment and prognosis of early chronic phase chronic myeloid Leukaemia (CML). This review article focuses on recent advances, culminating in the approval of nilotinib by the US Food and Drug Administration for the treatment of adult patients with newly diagnosed CML in the chronic phase.

Entities:  

Keywords:  CML; early chronic phase; treatment; tyrosine kinase inhibitor

Year:  2010        PMID： 23556068      PMCID： PMC3573384          DOI： 10.1177/2040620710387981

Source DB:  PubMed          Journal:  Ther Adv Hematol        ISSN： 2040-6207


  16 in total

Review 1.  BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.

Authors:  B A Burke; M Carroll
Journal:  Leukemia       Date:  2010-05-06       Impact factor: 11.528

Review 2.  Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia.

Authors:  Timothy Hughes; Susan Branford
Journal:  Blood Rev       Date:  2005-03-02       Impact factor: 8.250

Review 3.  An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.

Authors:  R T Silver; S H Woolf; R Hehlmann; F R Appelbaum; J Anderson; C Bennett; J M Goldman; F Guilhot; H M Kantarjian; A E Lichtin; M Talpaz; S Tura
Journal:  Blood       Date:  1999-09-01       Impact factor: 22.113

4.  Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.

Authors:  Jorge E Cortes; Michele Baccarani; François Guilhot; Brian J Druker; Susan Branford; Dong-Wook Kim; Fabrizio Pane; Ricardo Pasquini; Stuart L Goldberg; Matt Kalaycio; Beatriz Moiraghi; Jacob M Rowe; Elena Tothova; Carmino De Souza; Marc Rudoltz; Richard Yu; Tillmann Krahnke; Hagop M Kantarjian; Jerald P Radich; Timothy P Hughes
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

5.  IFNalpha activates dormant haematopoietic stem cells in vivo.

Authors:  Marieke A G Essers; Sandra Offner; William E Blanco-Bose; Zoe Waibler; Ulrich Kalinke; Michel A Duchosal; Andreas Trumpp
Journal:  Nature       Date:  2009-02-11       Impact factor: 49.962

6.  Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

Authors:  A Hochhaus; M Baccarani; M Deininger; J F Apperley; J H Lipton; S L Goldberg; S Corm; N P Shah; F Cervantes; R T Silver; D Niederwieser; R M Stone; H Dombret; R A Larson; L Roy; T Hughes; M C Müller; R Ezzeddine; A M Countouriotis; H M Kantarjian
Journal:  Leukemia       Date:  2008-04-10       Impact factor: 11.528

7.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Authors:  Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

Review 8.  Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

Authors:  Michele Baccarani; Jorge Cortes; Fabrizio Pane; Dietger Niederwieser; Giuseppe Saglio; Jane Apperley; Francisco Cervantes; Michael Deininger; Alois Gratwohl; François Guilhot; Andreas Hochhaus; Mary Horowitz; Timothy Hughes; Hagop Kantarjian; Richard Larson; Jerald Radich; Bengt Simonsson; Richard T Silver; John Goldman; Rudiger Hehlmann
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

9.  Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia.

Authors:  Gianantonio Rosti; Francesca Palandri; Fausto Castagnetti; Massimo Breccia; Luciano Levato; Gabriele Gugliotta; Adele Capucci; Michele Cedrone; Carmen Fava; Tamara Intermesoli; Giovanna Rege Cambrin; Fabio Stagno; Mario Tiribelli; Marilina Amabile; Simona Luatti; Angela Poerio; Simona Soverini; Nicoletta Testoni; Giovanni Martinelli; Giuliana Alimena; Fabrizio Pane; Giuseppe Saglio; Michele Baccarani
Journal:  Blood       Date:  2009-10-12       Impact factor: 22.113

10.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.

Authors:  Hagop M Kantarjian; Francis Giles; Norbert Gattermann; Kapil Bhalla; Giuliana Alimena; Francesca Palandri; Gert J Ossenkoppele; Franck-Emmanuel Nicolini; Stephen G O'Brien; Mark Litzow; Ravi Bhatia; Francisco Cervantes; Ariful Haque; Yaping Shou; Debra J Resta; Aaron Weitzman; Andreas Hochhaus; Philipp le Coutre
Journal:  Blood       Date:  2007-08-22       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.